We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Growing Use of Robots in Labs

By Biotechdaily staff writers
Posted on 21 Apr 2005
The lack of highly skilled labor that has been a major issue for medical device manufacturers and clinical and pharmaceutical research laboratories has been solved by having robots substitute for human labor in these applications, according to a new analysis by Frost & Sullivan (Palo Alto, CA, USA), a global growth consulting company.

Robotic systems are increasingly being adopted in order to improve productivity and efficiency as the demand for more sophisticated medical devices and newer drugs continues to grow. More...
The new analysis revealed that the total market in North America for industrial robots for medical and pharmaceutical applications in 2004 was U.S.$384 million and is expected to reach $668 million by 2011.

Robots have great potential to enhance efficiency and throughput in clinical laboratories, where samples need to be delivered from patients' bedsides to the test equipment and then to the analyzers on a daily basis. This is due to the distinct advantage they have over human-based delivery methods in terms of quicker transportation and a much greater handling capacity.

"As technology improves, more features are likely to be added to robotics systems, not only for delivery but also for testing and analyzing the samples,” noted Kishan Bhat, a research analyst with Frost & Sullivan. "This will enhance the efficiency of the robots, and in turn, boost the throughput of the laboratories.”

However, industrial robotics manufacturers face several challenges in their efforts to establish themselves in medical and pharmaceutical applications. Key among these is the incompatibility of their controller software with existing installed equipment. In most cases, this proprietary software is not upgraded frequently to meet the changing application requirements. The introduction of open architecture controllers is expected to reduce this challenge, however.

The emergence of stand-alone workstations in pharmaceutical labs is another strong challenge. While these can handle liquids for microplates within a limited capacity, they do not need manual intervention during the process, are less expensive, and occupy less space than total automated robotics systems. Because of these advantages, many pharmaceutical labs are opting for partial automation of their facilities even though fully automated robotics systems are more flexible and accurate. An increasing number of labs are considering microfluidics as an effective way of reducing costs, because of their ability to miniaturize chemical assays and thereby increase portability.


New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
HPV Molecular Test
BD Onclarity HPV Assay
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.